The utility and validity of cardiovascular diseases (CVD) risk scores are not well studied in sub-Saharan Africa. We compared and correlated CVD risk scores with carotid intima media thickness (c-IMT) among HIV-infected and uninfected people in Uganda.
INTRODUCTION
There is a growing burden of noncommunicable diseases in sub-Saharan Africa (SSA). 1 Mortality from noncommunicable diseases is disproportionately worse in lowand middle-income countries (LMIC) compared with highincome countries, and cardiovascular diseases (CVD) account for nearly half of these deaths. 2, 3 However, most estimates on global disease risk are populated from data outside the SSA region, where primary data on both cardiovascular disease epidemiology and mortality are limited. 3 An important priority for the region will be to expand the availability of CVD risk factors, outcomes, and mortality data to better define the CVD public health priorities and identify interventions to promote health that are scalable and sustainable in the local context. 4, 5 CVD risk prediction scores can quantify the burden of CVD at both an individual and population level and are widely accepted as one of the cornerstones of CVD management. 6, 7 Since the initial publication of a multivariate analysis to predict coronary disease risk using the Framingham Cohort approximately 50 years ago, multiple novel CVD risk prediction scores have been developed to address population-specific risk factors. 8 The Framingham lipidbased risk score (FRS-Lipids) is the most widely used and it has been updated with a nonlaboratory, office-based measurement using body mass index instead of lipids (FRS-BMI) to simplify risk estimation. 9 The Reynolds risk score most notably incorporated high-sensitivity C-reactive protein (hsCRP) and family history of CVD, which are independently associated with increased risk of CVD, but had not been included in previous CVD risk models. 10, 11 Recently, the American College of Cardiology and American Heart Association (ACC/AHA) derived a score from several geographic and ethnically diverse cohorts in the United States. 12 Finally, the Data collection on Adverse Effects of Anti-HIV Drugs (D: A:D) study collaborators developed an HIV-specific risk score to account for unique pathophysiology of CVD risk that has been postulated for HIV-infected populations. 13 Although CVD risk scores have the potential to enable risk stratification in resource-limited settings, all the above risk scores were developed from populations in resource-rich settings. Few studies have assessed CVD risk scores in SSA, [14] [15] [16] [17] and the utility and validity of commonly used CVD risk assessment tools in SSA remain unclear. Moreover, recent data suggest that standard CVD scores might underpredict true CVD in HIV-infected populations. 18 The objectives of this analysis were to compare and correlate CVD risk profiles with carotid intima media thickness (c-IMT), a surrogate marker of CVD, 19 among a population of HIV-infected people on antiretroviral therapy (ART) and community-based age-and sex-matched HIV-uninfected people in Uganda.
METHODS

Study Design and Participants
Data were collected as part of the Ugandan NonCommunicable Diseases and Aging Cohort (UGANDAC, NCT02445079), which has been described in detail elsewhere. 20, 21 Briefly, UGANDAC is a longitudinal cohort study evaluating the epidemiology of cardiovascular and pulmonary disease among older aged (age $40 years) people living with HIV in care in Mbarara, Uganda, and age-and sex-matched HIV-uninfected comparators enrolled from a village in the clinic catchment area. At each quarterly study visit, participants completed questionnaires on sociodemographic factors and medical history, underwent anthropomorphic and blood pressure measurements, and phlebotomy for hemoglobin A1c, fasting lipid profile, and hsCRP testing.
c-IMT Measurement
A sonographer trained at the University of Wisconsin c-IMT course performed all carotid ultrasonography using standardized protocols. 22 Ultrasonography was performed with a Sonosite M-Turbo (Sonosite, Bothell, WA). Images of the common carotid artery were collected from the anterior, lateral, and posterior position for a total of 6 images per participant. Farwall c-IMT was measured in 1-cm segments directly proximal to the carotid bulb, using semi-automated border-detection software (Sono-Calc, version 5.0; Sonosite). A board-certified cardiologist evaluated all images, and low quality images were discarded from the analysis with the mean value of all adequate images summarized as the mean c-IMT estimate for each participant. 21 
CVD Risk Prediction Scores
For each study participant, we calculated CVD risk with each of the following scores: Framingham lipid-based score (FRS-Lipids), Framingham BMI-based score (FRS-BMI), 9 Reynolds risk score (RRS), 10, 11 ACC/AHA score, 12 and the Data collection on Adverse Effects of Anti-HIV Drugs (D:A:D) score (see Table 1 , Supplemental Digital Content, http://links. lww.com/QAI/B153). 13 Those with a hemoglobin A1c equal to or greater than 6.5% or self-reported a history of diabetes and on medications were classified as having diabetes mellitus for scores that included that criterion. We categorized each individual into low, intermediate, and high CVD risk using standard classifications described with each risk score.
Statistical Analysis
We used descriptive statistics to summarize cohort characteristics, CVD risk scores distributions, and risk categories. We compared differences in risk factors between the HIVinfected and uninfected groups using the Wilcoxon rank-sum test for continuous variables and x 2 testing for categorical variables. We then compared the absolute FRS-BMI risk score with other scores using the Pearson correlation and then estimated Cohen's kappa coefficients to assess the degree of agreement between risk score categories (low, intermediate, or high risk). Finally, to estimate the validity of each risk score, we fit linear regression models using the risk scores as the predictor of interest and c-IMT as a surrogate outcome of CVD. Models were conducted both with the total cohort (except for the HIVspecific risk D:A:D score) and then stratified by HIV serosatus and sex. A P value ,0.05 was taken as the level of statistical significance. Analyses were conducted with Stata version 13 (StataCorp, College Station, TX).
Ethical Statement
The study was reviewed and approved by the ethics review committees of Mbarara University of Science and Technology and Partners Healthcare, Boston. Consistent with national guidelines, we also received clearance for the study from the Ugandan National Council of Science and Technology and from the Research Secretariat in the Office of the President.
RESULTS
We enrolled 105 (51%) HIV-infected people and 100 (49%) age-and sex-matched HIV-uninfected controls (Table 1 ). There were 54 (51%) and 50 (50%) women in the HIV-infected and control groups, respectively. The median age was 49 
Cardiovascular Disease Risk Categorization
HIV-uninfected individuals generally had higher CVD risk scores (Fig. 1) . For example, the median FRS-Lipids score among HIV-uninfected participants was 5.3% (IQR 3.2-9.3) compared with 3.6% (IQR 2.2%-6.2%) among the HIV-infected participants (P , 0.001). The Pearson correlation coefficients ranged from 0.91 to 0.97 (P , 0.001) for all pairs of risk scores (FRS-BMI vs. all other risk scores) except for the D:A:D score and Reynolds risk score, which had a lower Pearson correlation with FRS-BMI (rho = 0.80 and 0.83, P , 0.001, respectively).
The Framingham-based risk scores and the ACC/AHA classified most participants as low risk (71, 91% and 63, 80%, respectively), whereas the Reynolds and the D:A:D scores categorized most individuals in the intermediate or high-risk categories (53, 56% and 72%, respectively). Table 2 
Cardiovascular Disease Risk Correlation With c-IMT
In linear regression models, we found significant correlations between increasing CVD risk and higher c-IMT (P , 0.01 in all models) (see Fig. 2 and Supplemental Digital Content Figure 1 , http://links.lww.com/QAI/B153). Beta coefficients and corresponding P values for each model are shown in Table 3 .
DISCUSSION
In this analysis from a cohort of HIV-infected individuals on stable ART and a community-based HIV-uninfected comparator group, we found that the non-laboratory-based Framingham CVD risk prediction score (FRS-BMI) had high agreement with Framingham laboratory-based risk score and that all scores correlated relatively well with c-IMT, a surrogate marker of CVD. Our findings are in keeping with previous data that have demonstrated high agreement between non-laboratory-based and laboratory-based scores both in resource-rich and resource-limited settings. [14] [15] [16] [17] [23] [24] [25] Others have correlated higher c-IMT values and increasing FRS in a predominantly HIV-infected female population in South Africa and in another multicountry study that included individuals from South Africa. 26, 27 Although our findings offer additional support for non-laboratory-based CVD risk profiling with the use of an established surrogate marker of disease, an important next step will be to collect sufficient data to validate these scores with CVD outcomes. Nonetheless, the non-laboratory-based scores seem to offer a low-cost, feasible means of CVD risk profiling in resourcelimited settings.
Overall, there was good correlation between FRS-BMI and other scores. Agreement by major risk categories was imperfect, and in fact poor by kappa scores for many of the comparisons. Importantly, neither the Reynolds risk score (in HIV-uninfected individuals) nor the newer ACC/AHA score Although the Framingham and the D:A:D risk scores have been applied in various SSA populations, they have demonstrated a wide array of CVD risk profiles, presumably because study populations have also varied widely. For instance, a study of older age, post-menopausal women in western and southern Africa reported generally higher CVD risk based on the Framingham risk score when compared with our findings. 28 Conversely, a study of younger HIV-infected participants in southwestern Uganda reported relatively low CVD risk. 29 Differences in HIV-specific characteristics and CVD risk profiles at the time of risk estimation may partially explain these differences between our risk estimation with the D:A:D score when compared with other studies of HIVinfected participants in SSA. [30] [31] [32] We found that age-and sex-matched, communitybased, HIV-uninfected individuals had higher CVD risk scores when compared with HIV-infected individuals receiving ART in rural Uganda. The higher CVD risk scores in our study among HIV-uninfected participants were driven largely by a higher systolic blood pressure and smoking rates. We hypothesize that 1 potential mechanism of this observation could be the additional access to primary care services granted by routine, scheduled HIV care. 4 In fact, approximately 90% of HIV-infected ever-smoking participants were former smokers compared with 60% of HIV-uninfected participants; and among the HIV-uninfected participants who were diagnosed with hypertension, only 1 reported taking antihypertensive medications compared with 7 among the HIV-infected participants. HIV infection has been associated with lower risk of hypertension in several studies in the region, irrespective of treatment with antihypertensive medications, suggesting there might also be other causative mechanisms. [33] [34] [35] [36] [37] Alternatively, survivor bias may also account for the lower CVD risk seen in our study among HIV-infected participants. We limited recruitment of HIVinfected participants to those with at least 3 years of ART use, so by definition excluded those dying before linkage to care or early after ART initiation.
Many cohort studies in resource-rich settings have demonstrated higher incidence of CVD outcomes among HIV-infected populations compared with HIV-uninfected populations receiving clinical care. [38] [39] [40] [41] The increased CVD risk in the setting of HIV infection was recently shown to be similar to the increased CVD risk from diabetes in the United States, 42 which has been well recognized as a major risk factor for CVD. 43 A related outstanding question is whether standard CVD risk scores appropriately estimate risk for HIVinfected populations in SSA and other parts of the world. 44 In our analysis, the D:A:D score correlated well with c-IMT, but notably predicted much greater proportions of individuals with intermediate or high risk than other scores. Although our Our results should be interpreted in the context of limitations. First, this is a cross-sectional study, so relationships between CVD risk profiles and atherosclerotic burden cannot be presumed to be causative. Second, we attempted to correlate CVD risk scores with a surrogate marker of CVD, 19 as opposed to future risk of coronary heart disease and stroke, which the scores were designed to predict. Although some studies have not demonstrated c-IMT as a strong surrogate for CVD, 50 most studies in the field have, 19 and it is a useful and feasible measure in resource-limited settings where more advanced techniques (eg, coronary angiography and calcium scoring) are not available. Large, adequately powered, prospective studies or registries that include valid measures of these outcomes will be required to more accurately characterize CVD risk in the region. It is likely to be many years before the infrastructure and data are available to assess true cardiovascular outcomes in this region of the world, and as such preliminary data with surrogate measures are useful to generate hypotheses and advance the field.
In conclusion, we report that FRS-BMI, a simple noninvasive CVD risk assessment using BMI in place of laboratory-based lipids data, had high agreement with a laboratory-based FRS and correlated well with preclinical atherosclerosis among individuals in SSA. This score might offer a simple and feasible approach to improving CVD risk assessment in resource-limited settings. We also noted lower CVD risk scores and c-IMT among HIVinfected participants and that this difference seemed largely driven by modifiable risk factors such as lower blood pressure and smoking cessation. Further work will be necessary to reconcile the observed lower CVD risk in the context of persistent inflammation associated with HIV infection.
